# A Phase II Study of Dacomitinib in Progressive Brain Metastases

> **NCT02047747** · PHASE2 · TERMINATED · sponsor: **David Piccioni, M.D., Ph.D** · enrollment: 4 (actual)

## Conditions studied

- Brain Cancer

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT02047747
- **Lead sponsor:** David Piccioni, M.D., Ph.D
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2016-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047747, "A Phase II Study of Dacomitinib in Progressive Brain Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02047747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*